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Abstract
Background: Postinfectious cough (PIC) is a common condition that affects millions of people worldwide every year.
There is Western medicine for this condition but the treatment effect is often incomplete. Traditional Chinese medicine
(TCM) has been increasingly prescribed for patients with PIC. Preliminary trials on Qing-Feng-Gan-Ke-Granules (QFGKG)
conveyed promising results in treating PIC. This protocol describes an ongoing phase III randomized controlled clinical
trial, designed according to a novel methodology of “one study, one primary outcome”, with the objective of
evaluating the efficacy and safety of QFGKG in patients suffering from PIC.
Methods/Design: This is a multicenter, phase III, randomized, double-blind, parallel-group, placebo-controlled clinical
trial, comprising two simultaneously conducted study parts, part A and part B, intending to investigate two primary
outcomes, i.e. time to cough resolution and cough symptom score, respectively. A total of 480 patients, aged 18 to
65 years, who complain of an ongoing persistent cough that has been lasting ≥3 weeks, will be recruited from six
participating sites and then randomized to receive QFGKG 12.0 g twice daily or placebo 12.0 g twice daily. Each part
will enroll 240 patients, with 180 patients being allocated to the QFGKG group and 60 to the placebo group.
Discussion: Although traditional Chinese medicine is a structured intervention that has shown some promise in
treating persistent cough, existing unconvincing evidence has noted limitations. This is a rare well-designed and
rigorously-controlled, randomized, double-blind trial to evaluate the effects and safety of a Chinese herbal medicine in
patients with postinfectious cough, providing tangible benefits for clinical research. Results of this trial are inclined to
be conjectured as more truthful by implementing separate study parts that specifically estimate exclusive primary
outcome. It will not only provide robust clinical evidence on the efficacy and safety of QFGKG for postinfectious cough,
but will also provide a critical piece of information on the availability and superiority of a novel methodology for future
clinical trials. The current trial is ongoing with recruitment of the predetermined number of patients being in progress.
Trial registration: The two parts of this trial were separately registered with the Chinese Clinical Trial Registry:
ChiCTR-TRC-13003278 (part A); and ChiCTR-TRC-13003337 (part B).
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Background
Cough is the most common symptom presenting to
primary healthcare services. Postinfectious cough (PIC) is
considered as one of the top causes of subacute cough,
which occurs in 11 to 25 % of patients with upper respira-
tory tract infection (URTI) [1, 2]. It involves a persistent
cough lasting ≥3 weeks or even months [3] (but normally
< 8 weeks) secondary to the acute symptoms of a common
cold or upper respiratory tract infection (URTI) [4, 5].
Although PIC is always self-limited and is not associated
with severe debilitation or mortality, persistent cough may
impair the quality of daily life [4]. Therefore, many
patients with PIC are frequently impelled to seek medical
help [6].
Aside from pertussis, however, despite the fact that many
pathogenic agents including respiratory viruses (particularly
respiratory syncytial virus, adenoviruses, parainfluenza, and
influenza), M pneumoniae and Chlamydophila pneumoniae
have been implicated in children [4, 5, 7], the role of infec-
tious aetiology in PIC in adults is rarely confirmed till now
[8]. Poor knowledge on the pathogenesis of PIC, which is
supposed to be frequently multifactorial [2, 8–10], results
in a diagnostic challenge for physicians. Patients are
constantly investigated for other causes of persistent
cough [6]. Therapy with antibiotics has no role, as there is
no evidence that bacterial infection plays a role in adult
patients [4, 5]. Cysteinyl leukotrienes were considered to
be involved in the pathogenesis of PIC in recent studies,
however, montelukast failed to effectively treat PIC in a
latest randomized trial [11], leading to a controversy on its
role in PIC. Therefore, PIC can be a troublesome problem
for physicians and patients alike [6]. Currently available
therapies, including inhaled ipratropium, inhaled or oral
corticosteroids, central acting antitussive agents such as
codeine and dextromethorphan, can only be used for
symptom relief [4–7, 12, 13]. They have not been proved
to be effective in reducing the cough duration or improv-
ing the quality of life [4]. And above all, a range of adverse
outcomes including blurred vision, confusion, difficulty in
urination, drowsiness or dizziness, body rash/itching,
nausea or vomiting, constipation, diarrhea, sedation,
nervousness are elicited occasionally [14–16]. For these
reasons, complementary and alternative medicine is
becoming more and more popular in patients with PIC,
such as a combination of honey and coffee [6] as well as
traditional herbal medicines.
The use of traditional Chinese medicine (TCM) as a
complementary and alternative therapy for cough can be
dated back to thousands of years ago. People in China who
suffer from a persistent cough always give first priority to
TCM. With an increasing number of TCM formulas
developed for clinical use, an overview to facilitate the
discussion of its pros and cons is warranted. A recent
comprehensive systematic review of randomized controlled
trials demonstrated potential curative effects and reassured
the safety of TCM in the management of PIC [17]. Unfor-
tunately, due to the undesirable quality of included studies,
the definite effect of TCM turned to be inconclusive in this
review. Therefore, a rigorously designed randomized trial
becomes imperative.
TCM offers a holistic vision on disease, and syndrome
differentiation is the cornerstone of TCM prescription.
Differentiation means comprehensive analysis, and syn-
drome refers to symptoms and signs. Differentiation of
syndromes implies that the patient’s symptoms and signs
collected by the four diagnostic methods (inspection,
auscultation ant olfaction, inquiry, pulse-taking and palpa-
tion) are analyzed and summarized to identify the etiology,
nature and location of a disease, thereby determining what
syndrome the disease belongs to. Based on both clinical
experience and literature review, “pathogenic-wind invading
lung syndrome” is considered as the most common TCM
syndrome in patients with PIC [17]. TCM patent drug
Qing-Feng-Gan-Ke-Granules (QFGKG), designed on the
basis of a classic formula, comprises four widely used herbal
plants (Ephedra sinica Stapf, Sinomenium acutum, Stemona
japonica (Blume) Miq., and Aster tataricus L.f.). It has been
shown that QFGKG is very effective in dispelling wind and
relieving cough and is specifically appropriate for treating
“pathogenic-wind invading lung syndrome”. Unpublished
preliminary phpartacodynamics studies in rats showed that
QFGKG could significantly alleviate sulfur dioxide-induced
cough and ammonium hydroxide-induced cough, increase
the tracheal phenolsulfonphthalein excretion, improve the
peritoneal capillary permeability reduced by acetic acid, re-
lieve asthma caused by acetyl choline and histamine inhal-
ation, inhibit carrageenin-induced toes swelling, suppress
dinitrochlorobenzene-induced delayed type hypersensitiv-
ity, which suggests its antitussive, anti-inflammatory and
immunosuppressive properties. Subsequent clinical studies
investigated its efficacy and feasibility in individuals with
PIC [18, 19]. In addition, a previous multi-center phase II
trial [20] investigated the dose-effect relationship and dose-
safety relationship of QFGKG, with primary outcomes of
time to cough relief and time to cough resolution, as well
as secondary outcomes of cough symptom score, cough
recovery rate, TCM curative effect, and Chinese version of
cough-specific quality of life questionnaire (CQLQ) score
[21]. In this phase II trial, 180 patients were enrolled and
randomly assigned to receive high dose of QFGKG (12.0 g,
twice daily), or low dose of QFGKG (6.0 g, twice daily) plus
dummy QFGKG (6.0 g, twice daily), or dummy QFGKG
(12.0 g, twice daily) alone. Great improvements in all
outcomes, especially the time to cough resolution and
cough symptom score, were observed in the high dose
group. To the best of our knowledge, the phase II study
was the first well-designed placebo-controlled clinical trial
that reported TCM as a remedy for PIC, and its resultful
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conclusions provide foundations for the current phase III
trial.
“One study, one primary outcome”, a novel methodology
for clinical trial design, was published by China Food and
Drug Administration (CFDA). The core of this concept lies
in the supposition that study results will be more credible if
the whole study is single-mindedly and exclusively designed
for the unique outcome of main interest. Moreover, the
SPIRIT guidance suggests a minimum number of primary
outcomes in clinical trials because multiple primary
outcomes can introduce problems with multiplicity, select-
ive reporting, and interpretation when there are inconsist-
ent results across outcomes [22]. Thus, although this
design has not been widely implemented in clinical trials,
we prefer to conduct a tentative trial in an attempt to
provide some practical information.
The objective of this trial is to demonstrate the superior
efficacy and safe of QFGKG over placebo in adult individ-
uals with PIC by addressing the following hypotheses: (1)
That QFGKG will significantly shorten the cough duration
in patients with PIC; (2) That QFGKG will significantly
relieve the main clinical symptoms in patients with PIC;
(3) That QFGKG will increase the quality of life in
patients with PIC; (4) That QFGKG is safe and will not
result in any serious side effects; (5) That the novel design
methodology of “one study, one primary outcome” is
feasible and desirable in clinical trials.
Methods/Design
Study designs
This trial is designed as a randomized, double-blind,
placebo-controlled, parallel, phase III, superiority trial,
with allocations stratified by participating centers and
randomization performed as block at a ratio of 3:1, adher-
ing to the recommendation of “CONSORT statement”
[23] and “SPIRIT statement” [24]. As to the allocation
ratio, generally speaking, for a superiority trial using
placebo as a control intervention, 3:1 is recommended by
Provisions for Drug Registration (http://www.sda.gov.cn/
ypzcgl/ml.htm), taking into full consideration of statistical
significance, ethical requirement and risk-cost relation-
ship. This trial consists of two simultaneously conducted
study parts (part A and part B), currently involving six
participating centers across China: West China Hospital
of Sichuan University, Tangdu hospital of The Fourth
Military Medical University, Affiliated Hospital of Jiangxi
University of TCM, the Second Affiliated Hospital of
Tianjin University of TCM, Affiliated Hospital of Inner
Mongolia Medical University, and the First Affiliated
Hospital of Henan University of TCM. These centers were
defined primarily geographically. In each participating
center, a chief investigator will be appointed to be respon-
sible for the whole clinical process (subject recruitment,
intervention, follow-up, and data collection), adhering to
the study protocol. All personnel involved in this trial will
be trained prior to trial initiation. Training program is
about study protocol and relevant skills, especially the skill
of TCM syndrome differentiation. Staff placement and
individual responsibility will also be elaborated in the
training session. Besides, investigator’s brochure devel-
oped by the sponsor to facilitate the smooth running of
the trial will also be provided. This protocol is designed
largely depending on the results of previous phase II trial.
Both study parts have been registered with Chinese
Clinical Trial Registry (http://www.chictr.org). This proto-
col has two amendments. The schematic diagram and
Table 1 Schematic diagram of part A
Phase Supervision period
Time-point Baseline Visit 1 Visit 2 Visit 3
Day 0 8 ± 1 15 ± 2 Follow-up
Basic history collection ×
Informed consent ×
Demographics ×






Concomitant treatments × ×
Efficacy evaluation
Cough symptom score × × × ×
TCM syndrome score × × ×
Safety evaluation
Vital signs × × ×
Blood routine and urine
routine
× ×
Liver function (ALT, AST, STB,
ALP, γ-GT )
× ×
Renal function (Cr, BUN) × ×
ECG × ×










Remaining drug count ×
Patient record card distribution/
recycling
× ×
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flow chart of study process are shown in Tables 1, 2 and
Fig. 1.
Study participants
A total of 480 patients will be recruited and averagely
assigned to each part. Each center will recruit an equal
number of patients; 60 patients will be recruited at each
individual center in part A and 80 patients will be enrolled
at each individual center in part B. Patients, who are diag-
nosed as having PIC in one of the participating centers
according to the guideline issued by the Chinese Medical
Association [25], aged between 18 and 65 years, with a
TCM syndrome being differentiated as “pathogenic-wind
invading lung” based on the Guidelines for Clinical
Research of New Chinese Medicine [26], are eligible for
enrollment. Diagnosis criteria of PIC are presented in
Table 3. Inclusion and exclusion criteria are listed in
Table 4, and TCM syndrome diagnostic criteria, based on
State Administration of Traditional Chinese Medicine
Table 2 Schematic diagram of part B
Phase Supervision period
Time-point Baseline Visit 1 Visit 2 Visit 3
Day 0 6 ± 1 11 ± 1 Follow-up
Basic history collection ×
Informed consent ×
Demographics ×






Concomitant treatments × ×
Efficacy evaluation
Cough symptom score × × × ×
Cough VAS score × × ×
TCM syndrome score × × ×
CQLQ × ×
Safety evaluation
Vital signs × × ×
Blood routine and urine
routine
× ×
Liver function (ALT, AST, STB,
ALP, γ-GT )
× ×
Renal function (Cr, BUN) × ×
ECG × ×










Remaining drug count ×















Fig. 1 Flow chart of study process
Table 3 Diagnosis criteria for postinfectious cough
● Cough that has been present following symptoms of an upper
respiratory tract infection;
● Irritable dry cough or cough with small amounts of white mucus;
● Cough lasts for at least 3 weeks, but normally no longer than 8 weeks;
● Negative findings of chest radiograph;
● Negative results of bronchial provocation test and dilation test;
● Exclude other causes which could result in cough, such as upper
airway cough syndrome(UACS), cough variant asthma(CVA),
eosinophilic bronchitis(EB) and gastroesohageal reflux disease(GERC);
● Exclude severe pulmonary diseases including chronic obstructive
pulmonary disease(COPD),lung cancer, pulmonary tuberculosis, et al.;
● Exclude hypertension that involves use of angiotensin converting
enzyme inhibitor(ACEI) currently.
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guidelines [27], are elaborated in Table 5. Some discrepan-
cies should be noticed in the inclusion criteria of two
parts. Part A is designed to focus on the time when cough
can be resolved completely, thus patients’ cough severity is
relatively mild in order to yield more expected results. On
the other hand, part B is designed to calculate the dynamic
change in cough symptom score across four time-points
(see Table 2), so the cough severity of patients recruited in
this part is relatively severe for more obvious changes.
Patients must provide written informed consent
before any study procedures occur. Participants would
be excluded if they have any of the following conditions: 1)
misdiagnosis; 2) poor drug compliance (taking < 80 % or >
120 % of the required dosage); 3) inability to complete the
follow-up; 4) aggravations (such as dyspnea) that happen
within 24 h after taking the test drug (on this occasion,
patients will be treated with conventional therapies and
considered as an invalid case, whose last data would be col-
lected in Full Analysis Set (FAS)); 5) hypersensitivity or
other severe adverse reactions; and 6) voluntary withdrawal.
The trial will be terminated prior to its planned end date
in the context of the following accidents: 1) protocol devi-
ations; 2) inadvisable or flawed protocol; 3) compelling
suspension forced by authoritative agencies; and 4) dis-
continuation decided by the trial sponsor (managerial or
financial difficulties).
Randomization and blinding
Eligible patients will be randomized in a ratio of 3:1 to
QFGKG group or placebo group, with stratification by par-
ticipating center. A centralized randomization will be
employed. The random coding of each center as well as the
allocation sequence are generated electronically using SAS
6.12 software. Assignments are concealed in sequentially
prepared coded, sealed, opaque envelopes, in which the
corresponding intervention group of the randomization list
will be found. A professional statistician who is independ-
ent of intervention and data collection is appointed to
choose appropriate block length to ensure concealment. A
group of research assistants who are not involved in
recruitment, intervention or assessment of outcomes will
prepare the envelopes. Staff responsible for recruitment is
not allowed to take part in the group allocation. Only after
the former participant is enrolled and his/her baseline
testing is completed, the next envelope could be opened by
researchers responsible for allocation. Participants will be
randomized to the intervention group or the control group
in line with numbered envelope under instructions from
drug managers at each center. Blind codes along with
random seeds and block length will be recorded in dupli-
cate and delivered to Good Clinical Practice (GCP) Centre
Table 4 Selection criteria for eligible patients
● Inclusion criteria for study part
A
● Inclusion criteria for study part B
● Postinfectious cough ● Postinfectious cough
● Syndrome of “pathogenic-wind
invading lung”
● Syndrome of “pathogenic-wind
invading lung”
● Daytime cough symptom score
≥ 2 and/or nighttime cough
symptom score≥ 2
● Total cough symptom score≥ 4
● Persistent cough≥ 3 weeks
and≤ 6 weeks
● Persistent cough≥ 3 weeks and≤
6 weeks
● Age 18-65 years old ● Age 18-65 years old
● Agreement to participate and
provision of informed consent
● Agreement to participate and
provision of informed consent
● Exclusion criteria
● Body temperature > 37.3 °C
● Use of any medication intended
to treat PIC within
one week before enrollment
● ALT/AST > 1.5 times than the
upper limit of normal
reference values; Abnormal
blood creatinine; Urine protein
qualitative test > +;
Blood leukocyte count
< 3.0 × 109/L or > 10.0 × 109/L;
and/or neutrophil percentage > 80%
● History of any severe underlying
diseases
(e.g. cardiovascular, hematological,
hepatic, renal); or other
life-threatening disabling
conditions and concomitant
diseases (e.g. cancer, AIDS)
● Pregnancy or potential pregnancy
or lactation
● Hypersensitivity or allergy to any
component of the test drug
● Current psychiatric disorders or
legal disability
● Current or previous admission
to other investigational
drug studies within
3 months before enrollment
● Inability to complete the trial
as decided by the investigators
Table 5 Diagnostic criteria for TCM differentiation of
“pathogenic-wind invading lung syndrome”
Item Symptoms and signs
*Primary symptom persistent cough
Secondary symptoms 1) *throat itching, cough sensitivity to
cold air, heat air or strange odors and/or;
2) sticky and scanty sputum, dry throat
and chest congestion
*Tongue picture slight red tongue proper with/without
red tip; thin white tongue coating
*Pulse condition normal or floating pulse
* Items which must be satisfied for a diagnosis of TCM differentiation of
“pathogenic-wind invading lung syndrome”
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of West China Hospital and the sponsor for safekeeping.
Patients and all engaged personnel including the sponsor
remain blind to allocation and intervention throughout the
whole process. Placebo will be packaged with imitative
similarity in appearance, smell and taste with QFGKG.
However, personnel who are designated to prepare drug
packaging and labeling will not be blinded. The prepared
emergency code-break envelope that contains allocation
information, and emergency measures as well as contact
details of the responsible department will be distributed to
study centers along with drugs. Patients reported side
effects will be recorded in the case report forms (CRFs)
detailedly by physicians at visit 1 and visit 2. If an unpre-
dictable severe adverse event happens, the chief investigator
is qualified to open the emergency envelope and guide
physicians to treat the patient according to emergency mea-
sures. The patient must be withdrawn and be followed up
until he/she recuperates. In this case, the chief investigator
should report the case to hospital ethical committee and
drug administration agency. The broken code and reasons
for unblinding should be recorded on CRF. Meanwhile,
severe adverse event report form (SAERF) will also be com-
pleted. During the revealing, allocation information must
not be disclosed to the patient and any third party.
Sample size
The latest edition of Provisions for Drug Registration
issued by CFDA recommends a minimum number of
300 for subjects enrolled in the trial group in a phase
III clinical trial. Sample size calculation of this trial
results in 24 patients in total for part A (18 in the
QFGKG group and 6 in the placebo group) and 56
patients in total for part B (42 in the QFGKG group
and 14 in the placebo group), respectively. Obviously,
the calculated patient number in the QFGKG group
is much smaller than the recommended one. Given the
above, we set the sample size according to the Provisions
for Drug Registration. 480 patients in total would be
included, with 360 being assigned to the QFGKG group
and 120 being assigned to the placebo group, considering
a maximal dropout rate of 20 %. Calculation assumed an
80 % power for a two-sided log-rank test at a 5 % signifi-
cance level.
Interventions
After enrollment, eligible patients will be randomly
assigned to receive twice daily QFGKG 12.0 g or twice daily
dummy QFGKG (placebo) 12.0 g. The use of placebo as a
comparator in this trial largely depends on empirical evi-
dence [17, 28, 29] and Guidelines for Clinical Research of
New Chinese Medicine [26]. Besides, the absence of gener-
ally recognized therapy and self-healing tendency of PIC
also support the use of placebo. QFGKG and placebo in
this trial are manufactured by Baotou TCM Co., Ltd. The
Latin names, English names and Chinese Pinyin of the four
herbs used in QFGKG are listed in Table 6. Both within-
group changes and between-group changes are assessed
across three time-points during treatment. As to the treat-
ment duration, a longer (14 days) treatment in part A is
conducted for the sake of more cured cases, while a shorter
treatment (10 days) in part B is enough for monitoring
noticeable changes in cough symptom score. A two-day
follow-up will be conducted for all patients. At the initial
drug dispensing stage, patients are advised to strictly follow
protocol instructions, which will be reiterated at each study
visit. Participants are requested to genuinely report their
daily dosage of drugs that have been actually taken and to
return unused ones to physicians at each study visit. Drug
using and returning will be recorded on CRF by physicians.
Unused drugs will be finally collected and counted by
drug managers and then be destroyed by the sponsor
at the end of the trial. All previous and concomitant
treatments, including drug and non-drug therapies,
taken one week before and during the intervention
will be recorded on CRF. Concomitant treatment for
comorbidities such as hypertension, diabetes and other
chronic conditions are permitted during the intervention.
Whereas, the use of antibiotics, Western or other antitus-
sives, and non-drug cough suppressing therapies such as
acupuncture and cupping are strongly discouraged to pre-
vent potential systemic effects. Participating centers are
required to record dropout cases and reasons, and also
side effects happen during the intervention.
Outcome measures
Part A
Primary outcome The primary outcome of part A is time
to cough resolution, i.e. the time to the first day when
cough completely disappears. Cough resolution is defined
as both daytime cough symptom score nighttime cough
symptom score graded as 0, for 48 h. If the total cough
symptom score is classified as 0 in the two successive
days, the previous day should be considered as the first
day when cough completely disappears (Note: cough
symptom score is used to assess cough symptoms within
the last 24 h). For example, if the total cough symptom
score of a patient is rated as 0 on the fifth day and the
Table 6 Latin name, English name and Chinese pinyin of the
four herbs
Latin name English name Chinese pinyin
Ephedra sinica Stapf Herba Ephedrae Ma Huang
Sinomenium acutum Caulis Sinomenii Qing Feng Teng
Stemona japonica (Blume) Miq. Radix Stemonae Bai Bu
Aster tataricus L.f. Aster tataricus Zi Wan
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sixth day after intervention, then the time to cough reso-
lution is regarded as five days.
Secondary outcomes Secondary outcomes of interest in
part A include cough symptom score, time to cough
relief and TCM curative effect. Cough relief is de-
fined as both daytime cough symptom score and
nighttime cough symptom score ≤ 1 or reduce by one
score, for 48 h. TCM curative effect is calculated as per-
centage of cumulative TCM symptom score reduction
(PSSR) estimated between baseline and post-intervention,
which is categorized into four grades, complete recovery
(PSSR ≥ 95 %), excellent effect (95 % > PSSR ≥ 70 %), mod-
est effect (70 % > PSSR ≥ 30 %) and no effect (PSSR < 30 %).
The TCM symptom score system used in the protocol fol-
lows the Guidelines for Clinical Research of New Chinese
Medicine [26], in which primary and secondary symptoms
are given graded scores. The TCM symptom score and
TCM signs system is provided in Fig. 2. TCM signs will
also be assessed, but not scored. PSSR is calculated accord-
ing to the following formula:
PSSR ¼ symptom score before treatment−symptom score after treatment




Primary outcome The primary outcome of part B is
cough symptom score, which will be assessed across base-
line, 6 ± 1 days into the intervention, post-intervention
(11 ± 1 days) and 2 days post-intervention if necessary.
Simplified cough symptom score (SCSS) recommended by
Chinese Medical Association [30] is developed based on
the Asthma and Cough Symptom Score Estimation
Method [31]. It consists of daytime score and nighttime
score, ranging from 0 to 3, respectively. The cough symp-
tom score scale is provided in Table 7. SCSS, which is usu-
ally used to determine the frequency and diurnal variation
of cough, and also to reflect the quality of life, has been
verified as reproducible and well-responsive to treatments
[32]. Daytime is arbitrarily defined as 8 a.m. to 8 p.m. and
nighttime as 8 p.m. to 8 a.m.
Secondary outcomes Secondary outcomes of part B in-
clude visual analogue scale (VAS) [33], cough recovery
rate, time to cough resolution, time to cough relief, TCM
curative effect and cough-specific quality of life question-
naire (CQLQ) score (Chinese version). The reliability, val-
idity and responsiveness of the Chinese version of CQLQ
had been approved [21]. The production and development
of this version were conducted followed the international
standard guideline [34] through the comprehensive pro-
cesses of translation, back-translation, committee review
and pre-testing technique use. Professor Irwin, the author
of the original CQLQ, granted the permission to produce
the Chinese version [21].
Safety outcomes
Safety outcomes in this trial include blood routine test,
urine routine test, stool routine test, electrocardiogram,
liver function test (ALT, AST, STB, ALP, and γ-GT) and
renal function test (Bun and Cr). These biological pa-
rameters will be monitored both before and after trial
intervention. Urine pregnant test (UPT) is supposed to
be done before enrolling a female patient of child-
bearing age.
Data management
Completed CRFs will be reviewed by both chief investi-
gators and a qualified research monitor delegated by
Fig. 2 TCM symptom score and TCM signs
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Beijing Qihuang Medicine Clinical Research Center.
CRFs will be delivered for data management. All study
data will be entered in computerized database using Epi-
Data 3.1 software by two data mangers independently,
and results will be cross checked for accuracy and
consistency. Data entered into the database can be ac-
cessible only through authorized identification code and
password. Moreover, missing data or false data, if there
is any, will be detected by designed application program
and recorded by data managers, who are qualified to
recheck the original CRFs to ensure the correctness,
completeness, and consistency of entered data. The data-
base would be locked after data input. Original CRFs will
be kept on file in a secure manner at individual partici-
pating sites by chief investigators.
Statistical analysis
Beijing Qihuang Medicine Clinical Research Center is in
charge of data statistical analysis. The statistical analysis will
be masked. A group of professional statisticians who are
independent of all the other process of the study would per-
form the statistical analysis. Full Analysis Set (FAS) would
be applied for all participants who have been randomly allo-
cated and have taken QFGKG or placebo. Non-completers
who never use any test drugs will be excluded. Missing
values of primary variations will be imputed using the last
observation carried forward (LOCF) approach according to
intention-to-treat (ITT) principle. Cases in Per Protocol Set
(PPS) are those who thoroughly adhere to the protocol
without absence of baseline characteristics. Analysis of pri-
mary outcome and curative effect will be carried out using
FAS approach and PPS approach. Safety Analysis Set (SS)
includes all randomized patients who have accomplished at
least one study visit. Participating centers are required to
sum up participants number in each set and list partici-
pants who are removed from PPS. The Chi-square test or
Fisher’s exact test will be performed for the categorical vari-
ables, and the Student’s t-test will be used for continuous
normally distributed variables. For data that is not
normally distributed, intra-group or inter-group differ-
ences before and after treatment will be analyzed by
Wilcoxon rank sum test. The proportion of patients
with adverse events in two groups will be compared
using the chi-square test or Fisher’s exact test. The
statistical significance level is set at P < 0.05 and rela-
tive risk (RR) with corresponding 95 % confidence
interval (CI) to compare dichotomous variables will
be calculated. Table 8 shows the method of analysis
for specific outcomes.
Ethics
This trial is conducted in accordance with the ethical
and scientific principles that originate from the Declar-
ation of Helsinki and GCP [35] and local regulations
(http://www.sda.gov.cn/ypzcgl/ml.htm). The trial has
been authorized by CFDA (Clinical Trial Approval No.
2010 L00279). The current protocol and written in-
formed consent have been approved by the Ethics Com-
mittee of Clinical Trials and Biomedicine of West China
Hospital of Sichuan University. Until the required quota
of participants is reached, all potential patients can join
in this trial through two ways, advertisement and review
of health records by respiratory physicians. The recruit-
ment advertisement has also been approved by the ethics
committee. Participants are promised to be paid 200
RMB as financial incentive for enrollment when the
whole trial is finished, and they will be informed detailed
information about this trial regarding objectives, proced-
ure, potential risks and benefits, and their rights and ob-
ligations prior to enrollment. An informed consent that
is written in easy-to-understand language will be given
to participants. Patients’ full understanding of the proto-
col and contentment to every response from physicians
must be ensured. Interventions will not be initiated until
the written informed consent is obtained from all partici-
pants. Physicians are required to give their contact details
to each patient recruited. As regards secrecy and confi-
dentiality, data of every single patient will be recorded an-
onymously, and any information that is suspected to
reveal patients’ identification will be concealed. Patients’
confidentiality will be preserved at all times during the
whole trial and their medical records will definitely be
properly archived in National Drug Clinical Trial Institu-
tion, not disclosed to any third party.
Discussion
Postinfectious cough, a common but not widely recog-
nized and understood disease, imposes a great burden on
both physical and mental health of patients. Exploring an
effective treatment for PIC is an urgent necessity. TCM is
a structured intervention that has shown some promise in
the management of persistent cough. A growing number
of clinical trials are studying the effect of TCM on PIC.
But unfortunately, existing unconvincing evidence makes
it awkward to interpret findings in a consistent manner or
Table 7 Cough symptom score scale




0 no cough during the day no cough during the night
1 occasional cough for short
periods
cough for short periods
before sleep or occasional
cough during the night
2 frequent coughing, which
did slightly interfere with
usual daytime activities
frequent coughing, which
did slightly interfere with
sleep
3 distressing coughs, which
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confirm a conclusion. Although our previous phase II trial
is the first study using TCM to treat PIC, some limitations
still exist [20], such as the absence of follow-up. This trial
aims to fill this gap by undertaking a well-designed multi-
centre, placebo-controlled, double-blind randomized trial
to evaluate the efficacy and safety of a TCM formula,
Qing-Feng-Gan-Ke-Granules. Moreover, this trial will be
an outstanding supplement to this area by providing tan-
gible benefits for PIC research.
In this trial, we conduct two simultaneous study parts
that are mutually independent but not mutually exclu-
sive. We aim to not only propose a new effective remedy
for PIC but also practice a novel methodology for clin-
ical trials, that is “one study, one primary outcome”. As
we all know, a well designed clinical trial is always
expected to answer multiple main clinical questions.
Nevertheless, sometimes it is unreasonable to assess
multi-primary outcomes in one study. In this trial, we
intend to investigate the effectiveness of QFGKG on
different clinical outcomes. In this case, it may be more
convincing and persuasive to study different groups of
patients and conduct different intervention durations to
achieve exclusive primary outcome by separating the ori-
ginal trial into study parts. We believe that if considering
the results of the two study parts as a whole, it would be
helpful not only for figuring out ongoing objectives but
also for clarifying further implications. Therefore, we
assume that this novel design contributes to maximized
efficacy, lower cost, a better risk-benefit ratio of treat-
ment and more convincing results with strong applica-
tion value and may be recommended for further clinical
intervention trials. This is the most all-important distin-
guishing feature of this trial. Another breakthrough in
this protocol is that we highlight the importance of two
clinical related outcomes, time to cough resolution and
quality of life, which are seldom assessed in previous
studies [14].
Several limitations and drawbacks of this study are as fol-
lows. Firstly, since we are going to conduct different inter-
vention durations in the two parts, some patients with
relatively mild cough would be treated for 14 days while
those with relatively severe cough will be treated for 10 days,
which is paradoxical and against common clinical practice.
Secondly, although a careful knowledge of medical history
Table 8 Outcomes and methods of analysis
Outcome/variable Hypothesis Measures Methods of analysis
Baseline balance test Quantitative outcomes (age, disease duration,
body temperature, heart/respiratory rate, blood
pressure)
T-test/Wilcoxon rank sum test
Qualitative outcomes (gender, marriage, race,
previous treatment)




Percent and cases of adherence in previous 10/
14
days < 80 %, > 120 % and 80 %-120 %
Chi-squared test/Fisher exact test
Concomitant treatments Percent and cases of concomitant treatments Chi-squared test/Fisher exact test
Intervention duration Formula: the last day using test drugs-the first
day using test drugs + 1
T-test/Wilcoxon rank sum test
Primary
Time to cough resolution improvement
occurred
Kaplan-Meier method/Log-rank test
Cough symptom score improvement
occurred




T-test/Wilcoxon rank sum test
TCM symptom score improvement
occurred
T-test/Wilcoxon rank sum test
TCM curative effect improvement
occurred
Percent and cases of four grades: complete





Questionnaire T-test/Wilcoxon rank sum test
Cough disappearance rate improvement
occurred
CMH Chi-squared test
Time to cough relief improvement
occurred
Kaplan-Meier method/Log-rank test
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and physical examination including serologic tests may pro-
vide clues to diagnosis, the diagnosis of PIC still largely
depends on clinical exclusion [5]. Therefore, the possibility
of misdiagnosis cannot be ruled out. Thirdly, an objective
cough measurement is not included in this study. Many
video and sound recording surveillance have been used in
clinic to objectively monitor the cough frequency and
severity [36–39]. However some studies reported a poor
relationship between cough frequency and cough symptom
score [37–39]. Furthermore, although operating a manual
recording instrument is easy for patients, it requires a good
compliance, otherwise, considerable errors could be in-
duced. In addition, how to effectively and sensitively distin-
guish and filter the external vocal interference, and also
record the weak electromyographic signals of pulmonary
muscles are still the technical bottlenecks for the develop-
ment of 24 h cough monitors. Besides, the expensive cost
also limits the use of cough recording surveillance. For the
above reasons, objective cough measurements are not in-
cluded in our study. Fourthly, the lack of data from old
people over the age of 65 fails to provide information about
the efficacy and safety of QFGKG in this group of patients.
Trial status
The recruitment process was initiated from May 01,
2013 and until now, a total of 318 participants have been
included.
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